Delivery Order SPE2DB25D9348-SPE2DB26FNMNC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,046.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. The award, issued on October 21, 2025, with an ultimate completion date of November 12, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a delivery order valued at $26,113.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, issued on October 24, 2025, with an ultimate completion date of November 17, 2025, carries no set-aside designation, indicating the award was made through competitive procurement. The delivery order is issued under DMS...
- The Defense Logistics Agency awarded a $50,212.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for EXPAREL (liposomal bupivacaine) 266 mg/20 ml vials. The delivery order was issued on October 16, 2025, with an ultimate completion date of November 6, 2025, and carries no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in unrestricted federal...
- The Defense Logistics Agency awarded a delivery order valued at $2,436.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 ml vials. The contract is a firm fixed-price delivery order with an ultimate completion date of November 7, 2025, and was awarded on October 17, 2025. This award carries no set-aside designation, demonstrating the vendor's competitive capability in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,042.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 mL vials. This firm fixed-price delivery order, issued on September 26, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation, indicating the award was made through full and open competition. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $3,046.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 ml vials. This firm fixed-price delivery order, issued on October 16, 2025, with an ultimate completion date of November 6, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a delivery order valued at $12,553.15 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, awarded on June 2, 2025, with completion targeted for June 24, 2025, represents a direct pharmaceutical supply requirement for federal healthcare operations. The award carries no set-aside designation, demonstrating...
- The Defense Logistics Agency awarded a delivery order valued at $12,057.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 133 mg/10 mL vials. This firm fixed-price delivery order, issued on September 9, 2025, with an ultimate completion date of September 30, 2025, represents a continuation of the agency's pharmaceutical supply chain operations without set-aside designation. The award leverages...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,042.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, awarded on September 19, 2025, with an ultimate completion date of October 10, 2025, represents a direct pharmaceutical supply fulfillment to support Department of Defense medical facilities. The award carries no...
- The Defense Logistics Agency awarded a delivery order valued at $7,531.89 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, awarded on September 12, 2025, with an ultimate completion date of October 3, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract involves no...
- SPE2DB25D9348Indefinite Delivery Contract
- SPE2DB25D9348-SPE2DB26FNMNCDelivery Order
The Defense Logistics Agency awarded a $25,106.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through its established presence in the military medical supply chain since 2001 and its extensive portfolio encompassing branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables. The PPV-G GEN V contract, awarded on November 13, 2025, with a completion date of December 31, 2036, provides a 30-month base period with three 30-month option periods and positions the company as a critical regional pharmaceutical supplier supporting DoD healthcare operations globally. The company maintains no identified subcontractor relationships, delivering products directly to support military medical requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.1k | 10/27/25 |